Clinical Trial Update: Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD [Phase 3]

View source ↗

Summary

Open-label long-term safety and efficacy study of viloxazine ER (SPN-812) in adults with ADHD completed; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Viloxazine extended-release capsule (viloxazine)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Attention-Deficit/Hyperactivity Disorder | Phase 3 | Status: COMPLETED | Results posted: 2024-02-13